Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 7Neuroendocrine Tumors 2Neoplasm Metastasis 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Sarcoma 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Liver Neoplasms 1Liver Malignancy 1Hepatic Malignancies 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 112Cisplatin 76Oxaliplatin 44pembrolizumab 34Fluorouracil 32Capecitabine 30durvalumab 27Leucovorin 26lenvatinib 23Magnetic Resonance Spectroscopy 15Irinotecan 14Nivolumab 12Biopsy 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Platinum 8Folfox protocol 8Carboplatin 81,2-diaminocyclohexaneplatinum II citrate 8tremelimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × Yttrium-90 × Clear all
NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Beth Israel Deaconess Medical Center

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT06375915 2024-05-24

PM-CARE

IRCCS San Raffaele

Phase 2 Unknown
33 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡